Patients who would benefit from HCL won’t always ask about it

Are you thinking big enough when it comes to switching your adult patients from multiple daily injections?

The standards for insulin delivery for type 1 diabetes (T1D) have changed. NHS England describes hybrid closed loop (HCL) as “the next step in the evolution of diabetes technology”.1 NICE recommends hybrid closed loop as an option for eligible people with type 1 diabetes.2

NHS England

NICE coverage eligibility criteria

According to the NICE Hybrid Closed Loop guidance (TA943), HCL technology is recommended for three key groups:

  1. Adults with type 1 diabetes
    • Defined specifically as those who:
    • Have an HbA1c of 58 mmol/mol (7.5%) or higher,

      or

    • Experience disabling hypoglycaemia despite best possible management with CSII, rtCGM, or isCGM
  2. Children and young people with type 1 diabetes
  3. People with type 1 diabetes who are pregnant or planning a pregnancy

Omnipod® 5 Automted Insulin Delivery System has not been tested during pregnancy. DO NOT use the Omnipod® Algorithm technology in pregnant women.

Across the UK, many adult patients using multiple daily injections (MDI) are ready for something better.

Managing T1D can take a mental and emotional toll.3

But when a burdensome routine becomes familiar, making a change can feel out of reach or more trouble than it’s worth. Your patients need to know, however, that when it comes to HCL technology, they can unlock proven benefits with a switch to the simple Omnipod® 5 Automated Insulet Delivery System.

What could moving from injections to Omnipod 5 mean for your patients’ lives?

Hear one person’s experience of starting Omnipod 5.

The benefits of Omnipod 5 over MDI are clear.

Time in Range graph in mango color

Greater Time in Range

An average of 5.4 more hours a day in range versus MDI with CGM4

Lower Hba1c with a downward facing arrow in mango color

Lower HbA1c

0.8 percentage points lower with Omnipod 5 than MDI + CGM at 13 weeks4

Check mark within a circle in mango color

Insulin Satisfaction

Greater satisfaction with insulin delivery3

*RADIANT was a 13-week randomised trial in 188 people aged 4–70 years with type 1 diabetes, previously using MDI with continuous glucose monitoring (CGM), and baseline HbA1c of 7.5–11%. Time in range was 3.9–10 mmol/L (70–180 mg/dL). The study was conducted in the UK, Belgium and France.5
†Adjusted between-group HbA1c difference: −0.8 percentage points (95% CI −1.0 to −0.6; p<0.0001).
‡Reported by adults after three months with Omnipod 5, compared with their previous therapy.3

Omnipod Pod with the words "Within Range" to the right Omnipod Pod with the words "Within Range" to the right

Within Range Podcast: Dr. Emma Wilmot unpacks the incredible results of the RADIANT trial and discusses Omnipod 5’s impact on patients transition from MDI.

Equip your clinic to help more eligible patients access HCL

Email our team to discuss a planning session.

 

Preparing patients for the move to hybrid closed loop (HCL) technology

Dr Fiona Campbell shares her experience of preparing people for a change from MDI to AID, with planning and discussion to help them understand what to expect.

“In our experience, it’s actually something that can be quite straightforward.”

Dr Fiona Campbell, consultant, Leeds Children's Hospital, West Yorkshire, England. Paid speaker for Insulet.

Get the Most Out of Omnipod 5 for Your Adult Patients

On-demand webinar: Explore clinical evidence and practical case discussions with Dr. Jackie Elliott and Prof. Jean-Pierre Riveline.

Dr. Jackie Elliott and Prof. Jean-Pierre Riveline | October 2025 | 40:21

NHS, National Health Service; NICE, National Institute for Health and Care Excellence; HbA1c, glycated haemoglobin; CSII, Continuous Subcutaneous Insulin Infusion; rtCGM, Real-Time Continuous Glucose Monitoring; isCGM, Intermittently Scanned Continuous Glucose Monitoring; CGM, continuous glucose monitoring;

1. NHS England. Hybrid closed loop technologies: 5-year implementation strategy. 22 January 2024. Foreword. https://www.england.nhs.uk/long-read/hybrid-closed-loop-technologies-5-year-implementation-strategy/
2. National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Technology appraisal guidance TA943. 19 December 2023. https://www.nice.org.uk/guidance/ta943.
3. Polonsky WH et al. Diabetes Res Clin Pract 2022;190:109998. Prospective Omnipod 5 Trial involving 241 T1D patients aged 6-70. Study included questionnaire assessing psychosocial outcomes before and after 3 months of AID use. Adults experienced an improvement in mean insulin device satisfaction survey score: 4.07 vs. baseline 3.91, respectively.
4. Wilmot E, et al. Lancet (2026); A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2). HbA1c 13-weeks: control group 8% vs. Omnipod 5 group 7.2% (p<0.0001).

Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2).

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin.

The Omnipod 5 System is intended to operate as an automated insulin delivery system when used with compatible Continuous Glucose Monitors (CGM). When in automated mode, the Omnipod 5 system is designed to assist people with type 1 diabetes in achieving glycaemic targets set by their healthcare providers. It is intended to modulate (increase, decrease or suspend) insulin delivery to operate within predefined threshold values using current and predicted sensor glucose values to maintain blood glucose at variable target glucose levels, thereby reducing glucose variability. This reduction in variability is intended to lead to a reduction in the frequency, severity, and duration of both hyperglycaemia and hypoglycaemia.

The Omnipod 5 System can also operate in a manual mode that delivers insulin at set or manually adjusted rates. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin.

Warning: The Omnipod 5 Algorithm should NOT be used by anyone under the age of 2 years old. The Omnipod 5 Algorithm should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.